Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc - amlodipine (as besilate) - tablet - 10mg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc - clindamycin (as hydrochloride) - capsule - 300mg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma, inc.; distributor: chemway pharma, inc. - salmeterol (as xinafoate) , fluticasone propionate - powder for inhalation in capsule - 50mcg/500mcg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc.; distributor: chemway pharma inc. - salmeterol (as xinafoate) , fluticasone propionate - pre-metered dose dry powder for inhalation - 50mcg/ 250mcg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc.; distributor: chemway pharma inc. - tibolone - tablet - 2.5mg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc - cyproterone acetate , ethynylestradiol - tablet, film coated - 2mg+35mcg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc - lansoprazole - capsule, gastro resistant - 15mg

Philippines - English - FDA (Food And Drug Administration)

chemway pharma inc - montelukast (as sodium) - tablet, chewable - 5mg

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - paroxetine tablets, usp are indicated for the treatment of major depressive disorder.  the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.  the effects of paroxetine in hospitalized depressed patients have not been adequately studied.  the efficacy of paroxetine in m

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - major depressive disorder paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied